[go: up one dir, main page]

RU99120189A - DRUGS FOR TREATMENT OF A METABOLIC SYNDROME CONTAINING A HUMAN GROWTH HORMONE IN COMBINATION WITH A CORTZOL SYNTHESIS INHIBITOR - Google Patents

DRUGS FOR TREATMENT OF A METABOLIC SYNDROME CONTAINING A HUMAN GROWTH HORMONE IN COMBINATION WITH A CORTZOL SYNTHESIS INHIBITOR

Info

Publication number
RU99120189A
RU99120189A RU99120189/14A RU99120189A RU99120189A RU 99120189 A RU99120189 A RU 99120189A RU 99120189/14 A RU99120189/14 A RU 99120189/14A RU 99120189 A RU99120189 A RU 99120189A RU 99120189 A RU99120189 A RU 99120189A
Authority
RU
Russia
Prior art keywords
growth hormone
metabolic syndrome
administered
inhibitor
cortisol synthesis
Prior art date
Application number
RU99120189/14A
Other languages
Russian (ru)
Other versions
RU2198679C2 (en
Inventor
Пер Морин
Original Assignee
Кортендо АБ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9700642A external-priority patent/SE9700642D0/en
Application filed by Кортендо АБ filed Critical Кортендо АБ
Publication of RU99120189A publication Critical patent/RU99120189A/en
Application granted granted Critical
Publication of RU2198679C2 publication Critical patent/RU2198679C2/en

Links

Claims (16)

1. Способ борьбы с Метаболическим Синдромом у млекопитающего, при котором ингибитор синтеза кортизола и гормон роста вводят указанному млекопитающему в количествах, эффективных для лечения клинических проявлений Метаболического Синдрома.1. A method of combating a Metabolic Syndrome in a mammal, wherein a cortisol synthesis inhibitor and growth hormone are administered to said mammal in amounts effective to treat the clinical manifestations of the Metabolic Syndrome. 2. Способ снижения массы висцерального жира, связанной с Метаболическим Синдромом, у млекопитающего, при котором указанному млекопитающему вводят ингибитор синтеза кортизола и гормон роста в количестве, эффективном для снижения массы висцерального жира. 2. A method of reducing the mass of visceral fat associated with the Metabolic Syndrome in a mammal in which a cortisol synthesis inhibitor and growth hormone are administered to said mammal in an amount effective to reduce the mass of visceral fat. 3. Применение ингибитора синтеза кортизола и гормона роста в производстве лекарства для борьбы с Метаболическим Синдромом или для снижения массы висцерального жира, связанной с Метаболическим Синдромом. 3. The use of an inhibitor of the synthesis of cortisol and growth hormone in the manufacture of a medicament for controlling Metabolic Syndrome or for reducing the mass of visceral fat associated with Metabolic Syndrome. 4. Продукт, содержащий (а) ингибитор синтеза кортизола и (б) гормон роста, в качестве комбинированного препарата для одновременного, раздельного или последовательного применения при борьбе с Метаболическим Синдромом или для снижения массы висцерального жира, связанной с Метаболическим Синдромом. 4. A product containing (a) an inhibitor of cortisol synthesis and (b) growth hormone, as a combined preparation for simultaneous, separate or sequential use in the fight against Metabolic Syndrome or to reduce the mass of visceral fat associated with Metabolic Syndrome. 5. Медицинский продукт, содержащий ингибитор синтеза кортизола совместно с гормоном роста, для применения при борьбе с Метаболическим Синдромом или для снижения массы висцерального жира, связанной с Метаболическим Синдромом. 5. A medical product containing an inhibitor of cortisol synthesis together with growth hormone, for use in the fight against Metabolic Syndrome or to reduce the mass of visceral fat associated with Metabolic Syndrome. 6. Способ, применение или продукт по любому из пп. 1-5, где ингибитор синтеза кортизола выбран из группы, содержащей кетоконазол, эконазол и миконазол и их производные. 6. The method, application or product according to any one of paragraphs. 1-5, where the cortisol synthesis inhibitor is selected from the group consisting of ketoconazole, econazole and miconazole and their derivatives. 7. Способ, применение или продукт по п.6, где ингибитор синтеза кортизола представляет собой кетоконазол. 7. The method, use or product of claim 6, wherein the cortisol synthesis inhibitor is ketoconazole. 8. Способ, применение или продукт по любому из пп. 1-7, где введение, лекарство или продукт дополнительно включает в себя половой гормон, выбранный из тестостерона и природного или синтетического эстрогена. 8. The method, application or product according to any one of paragraphs. 1-7, where the introduction, the drug or the product further includes a sex hormone selected from testosterone and natural or synthetic estrogen. 9. Способ, применение или продукт по любому из пп. 1-8, где лечение длится в течение месяца или более. 9. The method, application or product according to any one of paragraphs. 1-8, where the treatment lasts for a month or more. 10. Способ, применение или продукт по любому из пп. 1-9, где ингибитор синтеза кортизола и гормон роста вводят ежесуточно в течение по меньшей мере 80% периода введения. 10. The method, application or product according to any one of paragraphs. 1-9, where the cortisol synthesis inhibitor and growth hormone are administered daily for at least 80% of the administration period. 11. Способ, применение или продукт по любому из пп. 8-10, где половой гормон вводят в виде препарата с регулируемым высвобождением, который высвобождает фармакологически эффективные количества полового гормона в течение по меньшей мере 50% периода введения. 11. The method, application or product according to any one of paragraphs. 8-10, where the sex hormone is administered in the form of a controlled release preparation that releases pharmacologically effective amounts of the sex hormone over at least 50% of the administration period. 12. Способ, применение или продукт по любому из пп. 1-11, где ингибитор синтеза кортизола и гормон роста вводят зависимым от времени образом. 12. The method, application or product according to any one of paragraphs. 1-11, where the cortisol synthesis inhibitor and growth hormone are administered in a time-dependent manner. 13. Способ, применение или продукт по п.12, где ингибитор синтеза кортизола вводят пациенту вечером, а гормон роста вводят утром. 13. The method, application or product according to item 12, where the cortisol synthesis inhibitor is administered to the patient in the evening, and growth hormone is administered in the morning. 14. Способ, применение или продукт по п.12, где ингибитор синтеза кортизола вводят пациенту по меньшей мере через 7 ч после гормона роста в любой данный день. 14. The method, use or product of claim 12, wherein the cortisol synthesis inhibitor is administered to the patient at least 7 hours after growth hormone on any given day. 15. Способ, применение или продукт по п.14, где ингибитор синтеза кортизола вводят по меньшей мере через 10 ч после гормона роста. 15. The method, use or product of claim 14, wherein the cortisol synthesis inhibitor is administered at least 10 hours after growth hormone. 16. Набор для применения при борьбе с Метаболическим Синдромом, содержащий: (а) первый контейнер, содержащий ингибитор синтеза кортизола; и (б) второй контейнер, содержащий гормон роста. 16. A kit for use in controlling Metabolic Syndrome, comprising: (a) a first container containing an inhibitor of cortisol synthesis; and (b) a second container containing growth hormone.
RU99120189/14A 1997-02-24 1998-02-24 Preparations for treatment of metabolic syndrome comprising human growth hormone in combination with cortisol synthesis inhibitor RU2198679C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9700642-3 1997-02-24
SE9700642A SE9700642D0 (en) 1997-02-24 1997-02-24 Means and ways of preventing and treating the metabolic syndrome

Publications (2)

Publication Number Publication Date
RU99120189A true RU99120189A (en) 2001-07-20
RU2198679C2 RU2198679C2 (en) 2003-02-20

Family

ID=20405901

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99120189/14A RU2198679C2 (en) 1997-02-24 1998-02-24 Preparations for treatment of metabolic syndrome comprising human growth hormone in combination with cortisol synthesis inhibitor

Country Status (12)

Country Link
US (1) US6274582B1 (en)
EP (1) EP1030682A1 (en)
JP (1) JP2001513082A (en)
KR (1) KR20000075626A (en)
CN (1) CN1178696C (en)
AU (1) AU743277B2 (en)
CA (1) CA2282467A1 (en)
NO (1) NO994053L (en)
NZ (1) NZ337123A (en)
RU (1) RU2198679C2 (en)
SE (1) SE9700642D0 (en)
WO (1) WO1998036770A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642236B1 (en) * 1998-12-14 2003-11-04 Cortendo Ab Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
AU768537B2 (en) * 1999-04-01 2003-12-18 Merck Sharp & Dohme B.V. Formulation comprising testosteron undecanoate and castor oil
AU2004200545B2 (en) * 1999-08-18 2007-05-17 Microdose Therapeutx, Inc. Metering and packaging of controlled release medication
US6428809B1 (en) 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
SE0001899D0 (en) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
ES2346961T3 (en) 2001-11-22 2010-10-22 Biovitrum Ab INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1.
US6967194B1 (en) * 2002-09-18 2005-11-22 Susan Matsuo Bio-identical hormones and method of use
US7383084B2 (en) * 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
US8133505B2 (en) * 2002-10-31 2012-03-13 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
US7662404B2 (en) * 2002-10-31 2010-02-16 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
IL152574A (en) * 2002-10-31 2009-09-22 Transpharma Medical Ltd Transdermal delivery system for dried particulate or lyophilized medications
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت method and pharmaceutical compositions for reliable achievements of acceptable serum testosterone levels
US20050031718A1 (en) * 2003-04-10 2005-02-10 Pharmanex, Llc Sea Buckthorn compositions and associated methods
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
DE102004034640A1 (en) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Method for systemic biocorrection of an organism
CA2594433C (en) * 2005-01-10 2014-12-30 Cortendo Invest Ab Compositions comprising the 2s,4r ketoconazole enantiomer for treating diabetes, metabolic syndrome and other conditions
KR100705981B1 (en) * 2005-10-12 2007-04-10 주식회사 리제론 Hair loss prevention or hair growth promoting composition containing human growth hormone
RU2009116632A (en) 2006-10-02 2010-11-10 Кортендо Инвест, Аб (Se) KETOCONAZOLE ENANTIOMER IN PEOPLE
US8439033B2 (en) 2007-10-09 2013-05-14 Microdose Therapeutx, Inc. Inhalation device
EP3607942A1 (en) 2008-11-07 2020-02-12 University of Sheffield Medicament and method of diagnosis
MY187036A (en) 2010-01-05 2021-08-27 Microdose Therapeutx Inc Inhalation device and method
DK2524039T3 (en) * 2010-01-11 2018-03-12 Curna Inc TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
US9925200B2 (en) 2014-06-17 2018-03-27 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100422162B1 (en) * 1994-08-09 2004-07-07 메타볼릭 신드롬 아이 지비지 에이비 Drugs for the treatment of diabetes type II, including ketoconazole

Similar Documents

Publication Publication Date Title
RU99120189A (en) DRUGS FOR TREATMENT OF A METABOLIC SYNDROME CONTAINING A HUMAN GROWTH HORMONE IN COMBINATION WITH A CORTZOL SYNTHESIS INHIBITOR
ES2325207T3 (en) COMBINATION INCLUDING VALSARTAN, AMLODIPINA AND HYDROCLOROTIAZIDA.
CA1165689A (en) Method of increasing oral absorption of polar bioactive agents
US20020013300A1 (en) Methods for improving size and appearance of a wound
BR0015284A (en) Controlled Release Hydrocodone Formulations
TWI312678B (en) Pharmaceutical composition comprising dapoxetine for treating sexual dysfunction
JP5558648B2 (en) Administration formulation for acetylcholinesterase inhibitors
JP2004531468A5 (en)
CN101934078A (en) Pharmaceutical composition comprising drospirenone and estrogen, and application thereof
TW200306799A (en) Combination of organic compounds
US3322626A (en) Medicinal composition for treating acne and method of using same
JP2001510795A5 (en)
AU723812B2 (en) Medicinal preparation and a method of medicinal action on human organism
US4054649A (en) Therapeutic compositions and the treatment of lesions of connective tissue
RU95101385A (en) Products containing g-csf and tnf-binding protein
JPS59199630A (en) Remedy for hypoovarianism
JP2004091473A (en) Therapeutic agent for improving chromatosis
EP0521057A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use.
US20230125425A1 (en) Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof
KR100271087B1 (en) Protein synthesis stimulator comprising tcf-2 for the treatment of hypoproteinemia
US20080268022A1 (en) Mehtods for treating and preventing ailments caused by human papillomavirus
KR900007434A (en) Therapeutics with cystatin as active ingredients
RU2577950C1 (en) Method of stimulating healing dermal burns
RU2220712C1 (en) Agent and set for normalization of functional disorders arising in preclimacteric and climacteric period
RU2006110550A (en) USE OF OXCARBAZEPINE FOR TREATMENT OF DIABETIC NEUROPATHIC PAIN AND FOR IMPROVEMENT OF SLEEP